TATA Health International Holdings Limited
1255.HK
Hong Kong Stock Exchange2.80
HKD
-0.09
- -
TATA Health International Holdings Limited
1255.HK
(Hong Kong Stock Exchange)
Recent
price
2.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- TATA Health International Holdings Limited (1255.HK) is an investment holding company principally engaged in the trading of footwear products through wholesale and retail channels; the trading of healthcare products; the provision of financial services, including securities advisory, investment management, and corporate finance advisory; and online medical services, such as medical advisory and consultation. The company offers footwear under brands including Clarks, Josef Seibel, The Flexx, and Petite Jolie, operating approximately 31 retail outlets in Hong Kong and 4 in Macau as of mid-2025, with geographic operations spanning Hong Kong, Macau, Australia, Taiwan, Mainland China, Thailand, and Malaysia. Founded in 1974 and headquartered at Flat F-J, 11F, Kwai Tak Industrial Centre, 15-33 Kwai Tak Street, Kwai Chung, New Territories, Hong Kong, it operates as a subsidiary of Great Wall International Investment X Limited, targeting consumers seeking comfort footwear and related healthcare offerings in the consumer cyclical retail sector. In recent developments, the company completed disposals of the Shang Ying Retail Group and Shang Ying Capital Group in September 2025 to independent third parties, streamlining operations amid lost records and minimal activity in non-footwear segments; it also disposed of Shang Ying International Group in April 2025 and deconsolidated Shangying Internet Medical (Shanghai) Co. Limited following its bankruptcy liquidation proceedings initiated in 2024. These transactions contributed to a one-off gain of approximately HK$34.7 million in the six months ended June 2025, shifting focus to the core footwear business, which generated all revenue of HK$42.1 million during that period despite a 41.8% year-over-year decline due to economic uncertainty. Healthcare, financial services, and online medical segments remain stagnant with nil revenue, reflecting strategic exits and operational challenges including customs issues and funding constraints.